Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia

Mary D. Ruppe, Xiaoping Zhang, Erik Imel, Thomas J. Weber, Mark A. Klausner, Takahiro Ito, Maria Vergeire, Jeffrey S. Humphrey, Francis H. Glorieux, Anthony A. Portale, Karl Insogna, Munro Peacock, Thomas O. Carpenter

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

X-linked hypophosphatemia (XLH) is characterized by lower extremity deformities that lead to bone and/or joint pain that result from decreased renal tubular reabsorption leading to hypophosphatemia caused by elevated levels of fibroblast growth factor 23 (FGF23). Objective: Validate the use of SF-36v2 Health Survey (SF-36v2) and the Western Ontario and McMaster Osteoarthritis Index (WOMAC) to measure previously unstudied health-related quality of life (HRQoL) in XLH patients and determine the change in HRQoL before and after treatment with KRN23, a human monoclonal anti-FGF23 antibody. Methods: Twenty-eight adult outpatients with XLH received up to four doses of KRN23 administered subcutaneously every 28 days. General HRQoL was measured with the SF-36v2 and condition-related HRQoL with the WOMAC at baseline and study endpoint as a secondary outcome of a Phase 1/2, open-label, multicenter, dose-escalation trial. Results: Testing for scale discriminant validity and convergent-divergent validity supported the use of these scales in the assessment of HRQoL in XLH. Both instruments indicated impairment of physical function at baseline with all mean scores showing a trend to improved health at study endpoint compared to baseline. When corrected for multiple comparisons, the score for Role Limitations due to physical health on the SF-36v2 which measures the patient's perception of their own chronic functional impairments due to poor physical health remained significantly improved (P <0.05), increasing to the mean score of US adults. For the WOMAC, Physical Functioning and Stiffness scores were significantly improved (P <0.05). Conclusion: KRN23 administration was associated with significantly improved patient perception of their Physical Functioning and Stiffness due to their disease. This study demonstrates that the SF-36v2 and WOMAC are valid tools for assessing HRQoL in XLH.

Original languageEnglish (US)
Pages (from-to)158-162
Number of pages5
JournalBone Reports
Volume5
DOIs
StatePublished - Dec 1 2016

Fingerprint

Familial Hypophosphatemic Rickets
Quality of Life
Antibodies
Health
Hypophosphatemia
Arthralgia
Ontario
Health Surveys
Osteoarthritis
fibroblast growth factor 23
Lower Extremity
Outpatients
Bone and Bones

Keywords

  • Fibroblast growth factor 23 (FGF23)
  • Health-related quality of life
  • KRN23
  • Rickets
  • X-linked hypophosphatemia

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia. / Ruppe, Mary D.; Zhang, Xiaoping; Imel, Erik; Weber, Thomas J.; Klausner, Mark A.; Ito, Takahiro; Vergeire, Maria; Humphrey, Jeffrey S.; Glorieux, Francis H.; Portale, Anthony A.; Insogna, Karl; Peacock, Munro; Carpenter, Thomas O.

In: Bone Reports, Vol. 5, 01.12.2016, p. 158-162.

Research output: Contribution to journalArticle

Ruppe, MD, Zhang, X, Imel, E, Weber, TJ, Klausner, MA, Ito, T, Vergeire, M, Humphrey, JS, Glorieux, FH, Portale, AA, Insogna, K, Peacock, M & Carpenter, TO 2016, 'Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia', Bone Reports, vol. 5, pp. 158-162. https://doi.org/10.1016/j.bonr.2016.05.004
Ruppe, Mary D. ; Zhang, Xiaoping ; Imel, Erik ; Weber, Thomas J. ; Klausner, Mark A. ; Ito, Takahiro ; Vergeire, Maria ; Humphrey, Jeffrey S. ; Glorieux, Francis H. ; Portale, Anthony A. ; Insogna, Karl ; Peacock, Munro ; Carpenter, Thomas O. / Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia. In: Bone Reports. 2016 ; Vol. 5. pp. 158-162.
@article{c98695f2e5ab41ef85d1fa2dc5fc9bf1,
title = "Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia",
abstract = "X-linked hypophosphatemia (XLH) is characterized by lower extremity deformities that lead to bone and/or joint pain that result from decreased renal tubular reabsorption leading to hypophosphatemia caused by elevated levels of fibroblast growth factor 23 (FGF23). Objective: Validate the use of SF-36v2 Health Survey (SF-36v2) and the Western Ontario and McMaster Osteoarthritis Index (WOMAC) to measure previously unstudied health-related quality of life (HRQoL) in XLH patients and determine the change in HRQoL before and after treatment with KRN23, a human monoclonal anti-FGF23 antibody. Methods: Twenty-eight adult outpatients with XLH received up to four doses of KRN23 administered subcutaneously every 28 days. General HRQoL was measured with the SF-36v2 and condition-related HRQoL with the WOMAC at baseline and study endpoint as a secondary outcome of a Phase 1/2, open-label, multicenter, dose-escalation trial. Results: Testing for scale discriminant validity and convergent-divergent validity supported the use of these scales in the assessment of HRQoL in XLH. Both instruments indicated impairment of physical function at baseline with all mean scores showing a trend to improved health at study endpoint compared to baseline. When corrected for multiple comparisons, the score for Role Limitations due to physical health on the SF-36v2 which measures the patient's perception of their own chronic functional impairments due to poor physical health remained significantly improved (P <0.05), increasing to the mean score of US adults. For the WOMAC, Physical Functioning and Stiffness scores were significantly improved (P <0.05). Conclusion: KRN23 administration was associated with significantly improved patient perception of their Physical Functioning and Stiffness due to their disease. This study demonstrates that the SF-36v2 and WOMAC are valid tools for assessing HRQoL in XLH.",
keywords = "Fibroblast growth factor 23 (FGF23), Health-related quality of life, KRN23, Rickets, X-linked hypophosphatemia",
author = "Ruppe, {Mary D.} and Xiaoping Zhang and Erik Imel and Weber, {Thomas J.} and Klausner, {Mark A.} and Takahiro Ito and Maria Vergeire and Humphrey, {Jeffrey S.} and Glorieux, {Francis H.} and Portale, {Anthony A.} and Karl Insogna and Munro Peacock and Carpenter, {Thomas O.}",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.bonr.2016.05.004",
language = "English (US)",
volume = "5",
pages = "158--162",
journal = "Bone Reports",
issn = "2352-1872",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia

AU - Ruppe, Mary D.

AU - Zhang, Xiaoping

AU - Imel, Erik

AU - Weber, Thomas J.

AU - Klausner, Mark A.

AU - Ito, Takahiro

AU - Vergeire, Maria

AU - Humphrey, Jeffrey S.

AU - Glorieux, Francis H.

AU - Portale, Anthony A.

AU - Insogna, Karl

AU - Peacock, Munro

AU - Carpenter, Thomas O.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - X-linked hypophosphatemia (XLH) is characterized by lower extremity deformities that lead to bone and/or joint pain that result from decreased renal tubular reabsorption leading to hypophosphatemia caused by elevated levels of fibroblast growth factor 23 (FGF23). Objective: Validate the use of SF-36v2 Health Survey (SF-36v2) and the Western Ontario and McMaster Osteoarthritis Index (WOMAC) to measure previously unstudied health-related quality of life (HRQoL) in XLH patients and determine the change in HRQoL before and after treatment with KRN23, a human monoclonal anti-FGF23 antibody. Methods: Twenty-eight adult outpatients with XLH received up to four doses of KRN23 administered subcutaneously every 28 days. General HRQoL was measured with the SF-36v2 and condition-related HRQoL with the WOMAC at baseline and study endpoint as a secondary outcome of a Phase 1/2, open-label, multicenter, dose-escalation trial. Results: Testing for scale discriminant validity and convergent-divergent validity supported the use of these scales in the assessment of HRQoL in XLH. Both instruments indicated impairment of physical function at baseline with all mean scores showing a trend to improved health at study endpoint compared to baseline. When corrected for multiple comparisons, the score for Role Limitations due to physical health on the SF-36v2 which measures the patient's perception of their own chronic functional impairments due to poor physical health remained significantly improved (P <0.05), increasing to the mean score of US adults. For the WOMAC, Physical Functioning and Stiffness scores were significantly improved (P <0.05). Conclusion: KRN23 administration was associated with significantly improved patient perception of their Physical Functioning and Stiffness due to their disease. This study demonstrates that the SF-36v2 and WOMAC are valid tools for assessing HRQoL in XLH.

AB - X-linked hypophosphatemia (XLH) is characterized by lower extremity deformities that lead to bone and/or joint pain that result from decreased renal tubular reabsorption leading to hypophosphatemia caused by elevated levels of fibroblast growth factor 23 (FGF23). Objective: Validate the use of SF-36v2 Health Survey (SF-36v2) and the Western Ontario and McMaster Osteoarthritis Index (WOMAC) to measure previously unstudied health-related quality of life (HRQoL) in XLH patients and determine the change in HRQoL before and after treatment with KRN23, a human monoclonal anti-FGF23 antibody. Methods: Twenty-eight adult outpatients with XLH received up to four doses of KRN23 administered subcutaneously every 28 days. General HRQoL was measured with the SF-36v2 and condition-related HRQoL with the WOMAC at baseline and study endpoint as a secondary outcome of a Phase 1/2, open-label, multicenter, dose-escalation trial. Results: Testing for scale discriminant validity and convergent-divergent validity supported the use of these scales in the assessment of HRQoL in XLH. Both instruments indicated impairment of physical function at baseline with all mean scores showing a trend to improved health at study endpoint compared to baseline. When corrected for multiple comparisons, the score for Role Limitations due to physical health on the SF-36v2 which measures the patient's perception of their own chronic functional impairments due to poor physical health remained significantly improved (P <0.05), increasing to the mean score of US adults. For the WOMAC, Physical Functioning and Stiffness scores were significantly improved (P <0.05). Conclusion: KRN23 administration was associated with significantly improved patient perception of their Physical Functioning and Stiffness due to their disease. This study demonstrates that the SF-36v2 and WOMAC are valid tools for assessing HRQoL in XLH.

KW - Fibroblast growth factor 23 (FGF23)

KW - Health-related quality of life

KW - KRN23

KW - Rickets

KW - X-linked hypophosphatemia

UR - http://www.scopus.com/inward/record.url?scp=84973163800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973163800&partnerID=8YFLogxK

U2 - 10.1016/j.bonr.2016.05.004

DO - 10.1016/j.bonr.2016.05.004

M3 - Article

VL - 5

SP - 158

EP - 162

JO - Bone Reports

JF - Bone Reports

SN - 2352-1872

ER -